

Special Issue

Expert Views on HPV Infection

Message from the Guest Editors

There are over 200 different human papillomavirus (HPV) types, which replicate in mucosal and cutaneous stratified epithelial surfaces giving rise to a wide range of persistent lesions. A subset of these viruses are oncogenic and have been demonstrated to be the causative agent of approximately 5% human cancers. Papillomaviruses infect the basal cells of the epithelium and establish a quiescent infection in the proliferative cells. As the infected cells differentiate, the productive life cycle is activated and virions are released from the surface of the epithelium. To support this life style, HPV's interact with, and manipulate, many key cellular pathways. The goal of this Special Issue is to obtain expert viewpoints on unresolved, controversial or emerging topics related to the natural history, evolution, biology, and disease association of HPV infection.

Guest Editors

Dr. Alison A. McBride

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Prof. Dr. Karl Munger

Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA

Deadline for manuscript submissions

closed (30 June 2017)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/8100

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).